News

GDP in the US: USP Chapter and Stimuli Article on MKT

In the Pharmacopeial Forum, PF 49(2), a proposal for a revised USP General Chapter <1079.2> "Mean Kinetic Temperature in the Evaluation of Temperature Excursions During Storage and Transportation of Drug Products" and a Stimuli Article "The Use of Mean Kinetic Temperature and the Need of Allowable Excursion Limits for Climatic Zone IVb" were published. Comments can be submitted until 31 May 2023.

More
Competent Authority of Czechia issues four new GDP Non-Compliance Reports

After the public access to the GDP Non-Compliance Reports in EudraGMDP did not function for several weeks, reports can now be accessed again. In the meantime, four new documents have been added by the competent authority of Czechia. In all cases, the companies did not provide approved storage facilities.

More
Questions and Answers from the ECA Webinar "GDP Update 2023" - Part 1

More than 60 participants attended the ECA Webinar "GDP Update 2023" in March. Many interesting aspects were discussed in the Q&A session. In total, about 20 questions were addressed to the speaker, Dr. Christian Grote-Westrick, which he answered in writing afterwards. We have compiled a selection of the questions and answers for you. You can read Part 1 here.

More
GDP in the US: New FDA Guidance for Industry on Definitions of Suspect Product and Illegitimate Product

The U.S. Food and Drug Administration (FDA) has published a new guidance entitled "Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act". The document clarifies the agency's interpretation of specific terms used in the definitions of "suspect product" and "illegitimate product". It is primarily intended to assist trading partners in meeting verification obligations.

More
FDA Warning Letter: Lack of Temperature and Humidity Control

The U.S. Food and Drug Administration (FDA) has published a Warning Letter sent to a drug manufacturer in Massachusetts, USA. Since the deficiencies found even concern simple GMP basic requirements, the company had to stop production and distribution in the meantime. What is actually interesting is that the FDA, among other things, explicitly criticizes the lack of a humidity control in the warehouse.

More
MHRA GMDP Symposia 2023

The Good Manufacturing and Distribution Practice Symposia 2023, organized by the Medicines and Healthcare products Regulatory Agency (MHRA) were held on 21 and 22 February 2023. The first day of the conference focused on regulatory developments in the area of Good Distribution Practice (GDP).

More
Two New PIC/S GDP Guidance Documents Published

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) has published two guidance documents for GDP inspectors, an Aide-Memoire on GDP inspections and a Q&A document. Both documents entered into force on 01 February 2023.

More
MHRA GMDP Symposien 2023

Am 21. und 22. Februar 2023 fanden zwei von der Medicines and Healthcare products Regulatory Agency (MHRA), der Zulassungs- und Aufsichtsbehörde für Arzneimittel in Großbritannien, organisierte Symposien zur guten Herstellungs- und Vertriebspraxis (Good Manufacturing and Distribution Practice Symposia 2023) statt. Der erste Konferenztag beschäftige sich schwerpunktmäßig mit den regulatorischen Entwicklungen im Bereich der guten Vertriebspraxis (GDP).

More
Zwei neue PIC/S GDP-Dokumente veröffentlicht

Das Pharmaceutical Inspection Co-operation Scheme (PIC/S) hat zwei Leitfäden für GDP-Inspektoren veröffentlicht, ein Aide-Memoire über GDP-Inspektionen und ein Q&A-Dokument. Beide Dokumente sind am 01. Februar 2023 in Kraft getreten.

More
Großhandel mit Arzneimitteln: Wann kann die Behörde die Erlaubnis aufheben?

Im Zusammenhang mit GDP-Non-Compliance-Reports liest man gelegentlich, dass ein Widerruf oder eine Rücknahme der Großhandelserlaubnis erfolgte. Aber was ist eigentlich der Unterschied zwischen Rücknahme und Widerruf, und in welchen Fällen kann die Behörde die Erlaubnis überhaupt aufheben?

More
x
Search